Abstract Number: 1118 • ACR Convergence 2024
The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study
Background/Purpose: The diagnosis of Behcet’s Disease (BD) is particularly challenging in non-endemic areas because of milder disease presentations and lack of specific tests. Prior studies…Abstract Number: 1633 • ACR Convergence 2024
Arthritis Activity Significantly Affects Quality of Life in Behcet’s Disease Patients
Background/Purpose: Arthritis associated with Behcet's disease (BD) has been reported to be related to patients' quality of life and associated with skin and mucosal lesions.…Abstract Number: 1896 • ACR Convergence 2024
The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics
Background/Purpose: The prevalence and incidence of Behcet’s syndrome (BS) in the UK is unknown at an unselected population level. BS may be associated with phenotypically…Abstract Number: 1556 • ACR Convergence 2023
Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome
Background/Purpose: Gastrointestinal involvement of Behçet's syndrome (GIBS) may require surgery in up to one third of the patients. We aimed to investigate the clinical characteristics,…Abstract Number: 1557 • ACR Convergence 2023
De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome
Background/Purpose: Monoclonal antibody tumor necrosis factor alpha inhibitors, particularly infliximab and adalimumab, are the most commonly used biological agents in the treatment of Behçet's syndrome…Abstract Number: 1558 • ACR Convergence 2023
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells (VC) on slit lamp examination at the time of diagnosis. However, the…Abstract Number: 1559 • ACR Convergence 2023
Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease
Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…Abstract Number: 1560 • ACR Convergence 2023
Decreased Level of Peripheral CLA+ Treg Is a Protective Factor of Nervous System Involvement in Behcet’s Syndrome: A Real-World Study in China
Background/Purpose: Behcet's syndrome (BS) is an autoimmune disease characterized by recurrent mucocutaneous ulcerations, vascular and nervous system involvement. While there have been a lot of…Abstract Number: 0044 • ACR Convergence 2023
Aberrant Mevalonate Metabolite Farnesyl Pyrophosphate-Induced Neutrophil Hyperactivation in Behçet’s Disease Pathogenesis
Background/Purpose: Behçet’s disease (BD) is a chronic vasculitis characterized by polymorphonuclear neutrophils (PMNs) hyperactivation with unknown etiology. The over-productions of neutrophil extracellular traps (NETs) and…Abstract Number: 1561 • ACR Convergence 2023
Clinical Features and Quality of Life of Japanese Bechet’s Disease Patients with Arthritis: A Japanese Monocentric Study
Background/Purpose: Arthritis is positioned as one of the main symptoms in Behcet's disease (BD), and it is a relatively frequent symptom that is observed in…Abstract Number: 0215 • ACR Convergence 2023
Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…Abstract Number: 1562 • ACR Convergence 2023
Behcet’s Disease Coagulopathy in a Racially Diverse Patient Population
Background/Purpose: Behcet's disease (BD) is a vasculitis with both thrombotic and bleeding complications which can make management challenging. Thrombosis is due to direct vascular inflammation,…Abstract Number: 0258 • ACR Convergence 2023
Understanding Monogenic Behçet’s Disease Pathophysiology: Impact of Pathogenic Variant L227X Associated with Autoinflammatory A20 Haploinsufficiency on Cellular Survival and Proliferation
Background/Purpose: A20, encoded by TNFAIP3, plays a critical role in NF-κB pathway regulation. A20 haploinsufficiency is a monogenic disorder form of Behçet's disease with a…Abstract Number: 1563 • ACR Convergence 2023
Methotrexate: A Safe and Effective Therapeutic Alternative in Behçet´s Disease
Background/Purpose: Behçet's disease (BD) is characterized by great clinical heterogeneity. The therapeutic strategy for BD could be tailored to the specific needs of the patient,…Abstract Number: 0692 • ACR Convergence 2023
Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity
Background/Purpose: Behçet's disease (BD) is an HLA class I-associated disorder, given its strong link to HLA-B*51. However, evidence of HLA class I restriction is lacking,…
ACR Meeting Abstracts